Table 2.
HI antibody response against the three 2011-2012 influenza vaccine antigens 1 and 6 months after IM-MF59 or ID vaccination
| Vaccine component | Group (N) |
Seroprotection rate (%) |
|
GMT |
|
MFI |
Seroconversion rate (%) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
[95% C.I.] |
[95% C.I.] |
[95% C.I.] |
[95% C.I.] |
||||||||
| Pre-vacc. | 1 month | 6 months | Pre-vacc. | 1 month | 6 months | 1 month | 6 months | 1 month | 6 months | ||
| A/Perth/16/09 (H3N2) |
IM-MF59 |
50.0 |
87.5** |
66.5 |
25.5 |
83.7** |
53.8* |
3.3 |
2.1 |
47.5 |
17.5 |
| (40) |
[37.3-62.6] |
[76.4-93.8] |
[52.0-76.1] |
[16.3-40.1] |
[44.8-156.2] |
[27.3-106.2] |
[1.9-5.7] |
[1.1-4.1] |
[35.1-60.2] |
[9.8-29.4] |
|
| ID |
50.0 |
92.5** |
67.5 |
28.3 |
131.3** |
69.1 |
4.6 |
2.4 |
60.0 |
30.0 |
|
| (40) |
[37.3-62.6] |
[82.6-97.0] |
[54.5-78.2] |
[14.7-54.5] |
[72.3-238.5] |
[33.2-144.0] |
[2.8-7.8] |
[1.3-4.4] |
[47.0-71.7] |
[19.6-42.9] |
|
| A/California/7/09 (H1N1) |
IM-MF59 |
25.0 |
72.5** |
40.0 |
15.0 |
55.0** |
22.0 |
3.7 |
1.5 |
50.0 |
7.5 |
| (40) |
[15.5-37.6] |
[59.7-82.4] |
[28.3-53.0] |
[9.2-24.5] |
[31.9-94.8] |
[13.0-37.3] |
[2.4-5.6] |
[1.1-2.0] |
[37.3-62.6] |
[3.0-17.4] |
|
| ID |
32.5 |
70.0** |
50.0 |
15.8 |
61.0** |
29.7 |
3.8 |
1.9 |
42.5 |
17.5 |
|
| (40) |
[21.7-45.5] |
[57.1-80.3] |
[37.3-62.6] |
[9.0-28.0] |
[31.4-118.4] |
[17.0-52.5] |
[2.2-6.8] |
[1.2-2.8] |
[30.5-55.5] |
[9.8-29.4] |
|
| B/Brisbane/60/08 | IM-MF59 |
55.0 |
75.0 |
57.5 |
31.5 |
50.8 |
31.5 |
1.6 |
1.0 |
10.0 |
0.0 |
| (40) |
[42.1-67.2] |
[62.4-84.4] |
[44.5 -69.5] |
[18.8–52.7] |
[29.6-87.0] |
[18.5-53.5] |
[1.3-2.0] |
[0.9-1.1] |
[4.6-20.5] |
[0.0-6.3] |
|
| ID |
40.0 |
75.0 |
60.0 |
20.0 |
62.9* |
35.9 |
3.2 |
1.8 |
40.0 $$ |
17.5 $$ |
|
| (40) | [28.3-53.0] | [62.4-84.4] | [47.0-71.7] | [12.7-32.0] | [35.6-114.7] | [20.7-62.2] | [1.7-6.0] | [1.0-3.1] | [28.3-53.0] | [9.8-29.4] | |
*p < 0.05 and **p < 0.01 comparing pre and post-vaccination data.
$$p < 0.01 comparing the two vaccine groups.